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Abstract:
 
Rutin (3, 3
 
′
 
, 4
 
′
 
, 5, 7-pentahydrohyflavone-3-rhamnoglucoside) is a flavonoid of the flavonol type. Rutin is found
in many plants and is also an important dietary constituent of  food and plant-based beverages. Rutin has several
pharmacological properties including antioxidant and cardioprotective activities. Also, it was identified that rutin is the
major low-density lipoprotein (LDL) antioxidant compound of mulberry in an 
 
in vitro
 
 study. The effects of rutin were
tested by using it as a supplement in a high-cholesterol diet. Male rats were fed a high-cholesterol diet (1 ml/100 g) for 4
weeks with rutin (10 or 100 mg/kg) or rutin 100 mg/kg and lovastatin supplementation to study the hypocholesterolaemic
effects of rutin on plasma lipid levels, hepatic enzyme activity, and liver tissue. Feeding the animals a high-cholesterol diet
resulted in marked hypercholesterolaemia and increased the serum level of LDL cholesterol (LDL-C). Rutin (at 100 mg/kg)
alone or in combination with lovastatin significantly reduced the levels of total cholesterol, and LDL-C and also markedly
decreased liver enzymes and weight in animals with a high-cholesterol diet. Our findings show that 100 mg/kg of rutin
alone or with lovastatin supplementation lowered liver weight and enzymes as well as plasma total cholesterol and LDL.
The hepatic histopathological results reflect the correlation of rutin and lovastatin combination with both liver weight and
the levels of plasma total cholesterol and LDL-C. These results indicate that rutin in combination with lovastatin has
 
increased anti-hypercholesterolaemic effects in an animal model.
 
Cardiovascular disease is now the most common cause of
death worldwide. Lipid levels are a metabolic risk factor for
cardiovascular disease and abnormalities in plasma lipoprotein
classes, and derangements in lipid metabolism rank among
the most firmly-established and best-understood risks factors
for atherosclerosis [1]. Plasma cholesterol levels are regulated
by the absorption of dietary cholesterol, excretion of choles-
terol via faecal sterols or bile acids, cholesterol biosynthesis,
and removal of  cholesterol from circulation. Numerous
previous studies have reported on the beneficial effects
of hepatic 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)
reductase and acyl-CoA: cholesterol acyltransferase inhibitors
of hypercholesterolaemia and atherosclerosis [2,3]. Low-
density lipoprotein cholesterol (LDL-C) transports cholesterol
from liver to tissues, whereas high-density lipoprotein
cholesterol (HDL-C) facilitates the translocation of choles-
terol from the peripheral tissues to the liver for catabolism.
Therefore, HDL-C has a useful effect in reducing tissue
cholesterol and an elevated ratio of  HDL-C in serum is
suggested together with a decreased level of  LDL-C to
reduce the risk of cardiovascular diseases [4].
In recent decades, it has been shown that a high-cholesterol
level and a high ratio of  saturated and monounsaturated
to polyunsaturated fatty acids in the blood predisposes
patients to vascular diseases, whereas a high dietary intake
of vegetables and fruits has the opposite effect [5,6]. Similarly,
it was reported that the intake of  flavonoids inversely
correlates with the plasma total cholesterol and LDL-C
concentrations in human beings [7]. Flavonoids are dietary
phenolic compounds that are widely distributed in nature
and are ubiquitous in plants, fruits, seeds and vegetables.
They possess anti-inflammatory, antiviral, antioxidant, hepat-
oprotective, antithrombotic, anticancerogenic, and other
biological effects [6].
Rutin (3, 3
 
′
 
, 4
 
′
 
, 5, 7-pentahydrohyflavone-3-rhamnoglucoside,
fig. 1) is a flavonoid of the flavonol type. Rutin is found in
many typical plants such as buckwheat and apples. It is also
an important dietary constituent of other foods and plant-
based beverages [8]. It was reported that rutin has several
pharmacological properties including antioxidant, anticarci-
nogenic, cytoprotective, antiplatelet, antithrombic, vasopro-
tective and cardioprotective activities [9–14]. Moreover,
rutin was found to be a neuroprotective agent and can
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ameliorate ischaemic reperfusion injury in the heart, brain,
and skeletal muscle [15–19]. Rutin was identified to be the
major LDL antioxidant compound of mulberry in an 
 
in vitro
 
study [20].
Therefore, in this study we examined the hypocholestero-
laemic effects of chronic administration of rutin in rats. It
was predicted that rutin would show hypocholesterolaemic
effects on the lipid profile and liver tissue because of its
properties.
 
Material and Methods
 
Animals.
 
Male Wistar rats (250–300 g) were obtained from the
Razi Institute (Karaj, Iran) and housed in groups of four per cage
under standard laboratory conditions. They were kept at constant
room temperature (21 ± 2
 
°
 
) under a normal 12 hr light : 12 hr
dark regime with free access to food and water. All animal
experiments were carried out in accordance with the European
Communities Council directive of 24 November 1986 (86/609/EEC)
in such a way as to minimize their suffering.
 
Chemicals.
 
Rutin and cholic acid were purchased from Sigma and
Merck. The other drugs used in this study were lovastatin (Tehran
Chemie Pharmaceutical Co, Iran), propylthiouracil (Iran Hormone,
Tehran, Iran), ketamine (Rotexmedica, GmbH, Germany), and
xylazine (Loughrea Co, Galway, Ireland).
 
Rat model of hypercholesterolaemia.
 
In rats, hypercholesterolaemia
was induced by gavage by daily administration of 1 ml/100 g body
weight of a cocktail containing in 1 l peanut oil: 100 g cholesterol,
30 g propylthiouracil and 100 g cholic acid over a period of 28 days.
The test compounds were administered simultaneously with the
cocktail [21].
The rats were divided into six groups of 10 animals in each
group. Group I received peanut oil orally (1 ml/100 g). Group II
received cocktail only as described above. Group III received cock-
tail and lovastatin (10 mg/kg). Group IV received cocktail and rutin
(10 mg/kg); Group V received cocktail and rutin (100 mg/kg); Group
VI received cocktail and lovastatin (10 mg/kg) and rutin (100 mg/kg).
 
Laboratory testing.
 
The lipid profile was analysed using commer-
cially available kits for HDL-C, LDL-C, total cholesterol, and
triglycerides (Pars Azmoon, Iran) and expressed in mg/dl. Serum
total T
 
4
 
 was determined by electrochemiluminescence immunoassay
(ECLIA, Roche, Germany) and expressed in nmol/l. Plasma
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were analysed using biochemical analysis kits (Pars
Azmoon, Iran) and expressed in IU/l.
Twenty-four hours after the last gavages, the rats were anaesthe-
tized with an injection of ketamine (60 mg/kg intraperitoneally) and
xylazine (6 mg/kg intraperitoneally). Blood samples were taken
from the left ventricle of the heart and collected into the test tubes
to obtain serum. Samples were subsequently centrifuged for 10 min.
(4000 
 
×
 
g). Serum was separated and used for the assessment of
total cholesterol, LDH-C, LDL-C, triglycerides, AST and ALT.
 
Liver histopathological assessment.
 
The livers were removed,
weighed and then cut into small pieces. Liver sections were fixed in
10% formalin, dehydrated in gradual ethanol (50–100%), cleared in
xylene, and embedded in paraffin. Sections (4–5 
 
μ
 
m thick) were
prepared and stained with haematoxylin and eosin dye for his-
topathological examination and observed under a microscope at a
magnification 100
 
×
 
 [22].
 
Statistics.
 
The data were expressed as mean values ± S.E.M and
tested with 
 
anova
 
 followed by the multiple comparison test of
Tukey–Kramer. Results with P < 0.05 were considered significant.
 
Results
 
Laboratory testing.
 
Feeding rats a high cholesterol diet in group II for 28 days
resulted in hypercholesterolaemia, as evidenced by high
serum total cholesterol and LDL-C, which were more than
the vehicle animals (table 1). Total cholesterol in groups IV,
V and VI was reduced by 21.1%, 17.6% and 18.4%, respec-
tively, compared to group II. The total cholesterol in group
III decreased by 14.7% compared to group II.
LDL-C levels in groups IV and V decreased by 48.4% and
47.5%, respectively, compared to group II. However, LDL-
C in groups III and VI was reduced by 59.4% and 55.2%,
respectively, compared to group II. The differences between
all groups were not as significant as regards HDL-C and
triglyceride levels. Furthermore, serum total T
 
4 
 
of  all groups
was significantly reduced compared to group I.
The measured plasma AST and ALT activities in rats that
consumed the rutin-supplemented high cholesterol diet and
lovastatin are shown in figs 2 and 3. The difference between
the plasma AST and ALT activities in group II and I was
significant (P < 0.001). Plasma AST in groups IV and V was
reduced compared to group II by 30.4% and 41.5%,
respectively. The difference between groups V and I was not
significant. However, the difference between groups IV and
Table 1.
Effects of rutin and lovastatin supplementation on the serum lipid profile in hypercholesterolaemic rats.
Parameter Group I Group II Group III Group IV Group V Group VI
TC (mg/dl) 143 ± 4 374 ± 2* 319 ± 1.5† 295 ± 16.4‡ 308 ± 12‡ 305 ± 2‡
TG (mg/dl) 80 ± 6 111 ± 14 102 ± 3 86 ± 18 95 ± 15 97 ± 8
LDL-C (mg/dl) 76 ± 3 281 ± 2* 114 ± 2‡ 145 ± 7‡ 147 ± 8‡ 126 ± 5‡
HDL-C (mg/dl) 49 ± 3 42 ± 1 38 ± 5 49 ± 1 35 ± 3 37 ± 3
T4 (nmol/l) 62 ± 2.3 12.6 ± 0.3* 12* 10.5 ± 0.1* 10.2 ± 0.3* 8.7 ± 0.5*
Group I: Vehicle; Group II: Cocktail; Group III: Cocktail + lovastatin (10 mg/kg); Group IV: Cocktail + rutin (10 mg/kg); Group V:
Cocktail + rutin (100 mg/kg); Group VI: Cocktail + lovastatin (10 mg/kg) + rutin (100 mg/kg).
Values are the mean ± S.E.M. for 10 rats. *P < 0.001 compared to group I; †P < 0.01, ‡P < 0.001 compared to group II, Tukey-Kramer Test.
TC, total cholesterol; TG, triglycerides.
 EFFECTS OF RUTIN ON LIPID PROFILE
 
255
 
© 2009 The Authors
Journal compilation
 
 © 2009 Nordic Pharmacological Society. 
 
Basic & Clinical Pharmacology & Toxicology
 
, 
 
104
 
, 253–258
 
I was significant (P < 0.05) (fig. 2). Moreover, groups IV and
V had a decreased plasma ALT compared to group II by
23.1% and 41%, respectively (fig. 3).
Plasma AST in group III was reduced by 55.2% compared
to group II. The difference between groups III and I was not
significant (fig. 2). Plasma ALT was reduced in group III by
9.8% compared to group II. Moreover, the differences
between groups III and I were significant (P < 0.01) (fig. 3).
Plasma AST in group VI was reduced by 43.5% compared
to group II. The difference between groups VI and I was not
significant (fig. 2). Also, plasma ALT was reduced in group
VI by 43.3% compared to group II and the difference
between groups VI and I was not significant (fig. 3).
 
Effect on liver weight : body weight ratio.
 
The ratio of liver weight : total body weight was signifi-
cantly higher in group II than in group I (P < 0.01) (table 2).
Moreover, liver weight : body weight ratio was not different
between groups V and VI in comparison with group I.
 
Histological results.
 
In group I, a normal lobular pattern, hepatic cells with
well-preserved cytoplasm, a prominent nucleus, and a
well-visualized central vein were observed (fig. 4A). In
group II, microvesicular fatty changes, small-droplet fat in
hepatocytes with centrally located nuclei, mononuclear
inflammatory infiltration, and venous congestion were
observed (fig. 4B). In group III, small-droplet fat in hepato-
cytes of zone III and mononuclear inflammatory infiltration
was observed (fig. 4C). In group IV, steatosis in zone III and
mononuclear inflammatory infiltration was observed (fig. 4D).
In group V, no steatosis or inflammation was found. However,
venous congestion was occasionally observed (fig. 4E). In
group IV, the appearance of the cells was similar to the control
group. Steatosis and inflammation were not found (fig. 4F).
 
Discussion
 
Rats are generally considered to be resistant to naturally-
occurring and experimentally-induced atherosclerosis [23].
High doses of dietary cholesterol combined with bile acids
and experimentally induced hypothyroidism have been
demonstrated to lead to the development of atherosclerotic
lesions in rats [24]. Therefore, in the current study hyper-
cholesterolaemia was induced in rats, evident from the total
cholesterol level in plasma after feeding the animals a
Fig. 2. Effect of rutin on plasma AST levels in
hypercholesterolaemic rats. Group I: Vehicle; Group II: Cocktail;
Group III: Cocktail + lovastatin (10 mg/kg); Group IV: Cocktail +
rutin (10 mg/kg); Group V: Cocktail + rutin (100 mg/kg); Group
VI: Cocktail + lovastatin (10 mg/kg) + rutin (100 mg/kg). Values
are the mean ± S.E.M. for 10 rats. *P < 0.05, ***P < 0.001
compared to group I, Tukey–Kramer test.
Table 2.
Effect of rutin and lovastatin supplementation on liver weight : body weight (LW : BW) ratio in hypercholesterolaemic rats.
Mean Group I Group II Group III Group IV Group V Group VI
LW : BW (mg/g) 40.3 ± 0.7 61.4 ± 3** 60.4 ± 3** 65.4 ± 3* 52.2 ± 4 55.3 ± 1.6
Group I: Vehicle; Group II: Cocktail; Group III: Cocktail + lovastatin (10 mg/kg); Group IV: Cocktail + rutin (10 mg/kg); Group V:
Cocktail + rutin (100 mg/kg); Group VI: Cocktail + lovastatin (10 mg/kg) + rutin (100 mg/kg).
Values are the mean ± S.E.M. for 10 rats.*P < 0.05, **P < 0.01 compared to group I, Tukey-Kramer test.
Fig. 3. The effect of rutin on plasma ALT levels in
hypercholesterolaemic rats Group I: Vehicle; Group II: Cocktail;
Group III: Cocktail + lovastatin (10 mg/kg); Group IV: Cocktail +
rutin (10 mg/kg); Group V: Cocktail + rutin (100 mg/kg); Group
VI: Cocktail + lovastatin (10 mg/kg) + rutin (100 mg/kg). Values are
the mean ± S.E.M. for 10 rats. **P < 0.01, ***P < 0.001 compared
to group I, Tukey–Kramer test.
 256
 
AMIR ZIAEE 
 
ET AL.
 
© 2009 The Authors
Journal compilation
 
 © 2009 Nordic Pharmacological Society. 
 
Basic & Clinical Pharmacology & Toxicology
 
, 
 
104
 
, 253–258
 
high-cholesterol diet. Serum total T
 
4
 
 of  all groups was
significantly reduced compared to group I, which showed that
all study groups had hypothyroidism (except the vehicle group).
After the model was established, the possible hypercholes-
terolaemic effects of chronic administration of rutin alone
or with lovastatin were examined in rats. In this context, the
serum lipid profile, liver enzymes, and tissue were investigated.
According to the results, the effects of different doses of
rutin (10 and 100 mg/kg) and lovastatin with rutin (100 mg/kg)
on reducing plasma total cholesterol were greater than
lovastatin alone. The effects of rutin groups and lovastatin
and lovastatin with 100 mg/kg rutin on reducing LDL were
statistically equal. However, it seems that the effects of
lovastatin alone and lovastatin with 100 mg/kg rutin were
greater than administration of rutin alone.
A hypercholesterolaemic diet caused an increase in
oxidative stress in the liver, resulted in an increase in AST
and ALT levels, and induced fatty liver [25,20]. Therefore, in
the present study, ALT and AST, apart from cholesterol,
were also evaluated to reveal the protective effects of rutin
on hepatic enzymes. As a result, it seems that supplementing
a high-cholesterol diet with 100 mg/kg rutin or lovastatin
and 100 mg/kg rutin could lower AST and ALT activities
more than 10 mg/kg rutin or lovastatin alone. As the liver
weight : body weight ratio indicates, it is possible that animals
that received rutin 100 mg/kg alone or with lovastatin with
their hypercholesterolaemic diets have less fat accumulation
in the liver.
In other studies, the influence of the flavonoids on the
endogenous regulation of cholesterol biosynthesis has been
Fig. 4. Haematoxylin and eosin stained section of the rat liver in the group I (Vehicle) (A), II (Cocktail) (B), III (Lovastatin 10 mg/kg) (C),
IV (Cocktail + rutin 10 mg/kg) (D), V (Cocktail + rutin 100 mg/kg) (E), VI (Cocktail + rutin 100 mg/kg + lovastatin 10 mg/kg) (F).
Magnification 100×.
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discussed and antiatherosclerotic effects of flavonoids have
been explained in several studies [6,27,28].
On the other hand, quercetin, one of the metabolites of
rutin, lowered the plasma lipid and hepatic cholesterol levels
in high-cholesterol-fed rats. Quercetin also decreased HMG-
CoA reductase activity. It was suggested that supplementation
of quercetin dihydrate and gallate promotes an increase in
faecal sterols, which in turn leads to a decreased absorption
of dietary cholesterol as well as lowered plasma and hepatic
cholesterol [29,30]. Thus, it is possible that rutin, by converting
to its active metabolite, decreased HMG-CoA reductase
activity and decreased absorption of dietary cholesterol.
Moreover, both rutin and quercetin have an antioxidant
effect, and rutin showed clear synergism with quercetin in
an 
 
in vitro
 
 study [31]. It has also been reported that quercetin
and rutin could suppress lipid peroxidation in biological
membrane systems such as mitochondria, erythrocytes, and
others [32,33]. Thus, the other possibility for the hepato-
protective effects of rutin may be related to antioxidant
activity to prevent liver injury. However, further studies are
needed to clarify the exact mechanism.
Another possible explanation for the decreased liver
damage and lower liver enzymes for the 100 mg/kg rutin
alone group or the group with rutin and lovastatin along
with a high-cholesterol diet in animals depends on the anti-
inflammatory effects of both drugs. Anti-inflammatory effects
of rutin were found in several studies [34,35]. Furthermore,
it is suggested that rutin has effective anti-inflammatory
effects in the chronic model of inflammation [36].
Statins also have an anti-inflammatory effect that is
independent of changes in the cholesterol level [37,38]. Fur-
thermore, the neuroprotective effects of statins against a
variety of CNS diseases have been studied [39,40].
In conclusion, our findings indicate that 100 mg/kg rutin
alone or with lovastatin supplementation lowered liver
weight as well as plasma total cholesterol and LDL. The
hepatic histopathological results reflect a correlation of
rutin and lovastatin combination with both liver weight and
the levels of plasma total cholesterol and LDL-C. However,
histopathological results show that liver injury in rats given
100 mg/kg rutin with lovastatin was less than in rats given
100 mg/kg rutin alone. Our data clearly indicate that the
antihypercholesterolaemic effects of rutin in an animal
model increased in combination therapy with lovastatin. It
seems that several mechanisms may contribute to the hyper-
cholesterolaemic effects of rutin.
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